Masaki Meguro

Title: Masaki Meguro: Innovator in Antibody-Drug Conjugates

Introduction

Masaki Meguro is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates. With a total of 7 patents to his name, Meguro's work focuses on innovative methods for treating tumors and diabetes.

Latest Patents

Among his latest patents, Meguro has developed methods for treating tumors by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate. This invention provides a novel approach using an antibody-pyrrolodiazepine derivative and a conjugate that utilizes the same. Additionally, he has created antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines. These compounds are classified as alkyl benzene sulfonyl ureas, which are useful as oral anti-diabetics.

Career Highlights

Meguro has worked with notable companies in the pharmaceutical industry, including Daiichi Sankyo Company, Limited and BTG International Limited. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Throughout his career, Meguro has collaborated with esteemed colleagues such as Narihiro Toda and Yusuke Ota. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Masaki Meguro's contributions to the field of biotechnology, particularly in antibody-drug conjugates, highlight his innovative spirit and dedication to improving medical treatments. His work continues to influence the landscape of therapeutic development.